Kirin Holdings Co (KNBWY) AI Stock Analysis

• Market Cap: $12.26B
• Dividend Yield: 2.27%
• Average Volume (3M): 1.95K
• Price to Earnings (P/E): 21.9
• Beta (1Y): -0.12
• Revenue Growth: 4.97%
• EPS Growth: -60.57%
• Country: US
• Employees: 31,934
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Beverages - Alcoholic
• EPS (TTM): 0.40
• Shares Outstanding: 914,000,000
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 1,950
• PEG Ratio: -0.59
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 0.71
• P/FCF Ratio: 26.56
• Enterprise Value/Market Cap: 1.60
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: 0.02
• Enterprise Value/Ebitda: 0.07
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.22
• Revenue Forecast (FY): $16.02B

• Rating: 58 Neutral
• Price Target: $15.00 ▲(3.16% Upside)

Kirin Holdings Co's overall stock score is primarily influenced by its mixed financial performance, with stable margins but declining revenue growth and cash flow challenges. Technical analysis indicates a neutral to slightly bearish outlook, while valuation concerns arise from a high P/E ratio. The absence of earnings call and corporate events data limits further insights.

Kirin Holdings Co Business Overview & Revenue Model

Company Description

Kirin Holdings Company, Limited is a Japanese multinational corporation primarily known for its beverages and food products. Founded in 1885, the company operates through several segments, including Alcoholic Beverages, Soft Drinks, and Food Products. Kirin is particularly recognized for its beer brands, as well as a diverse range of non-alcoholic beverages and dairy products. The company is committed to innovation and sustainability, focusing on health-oriented products and environmental stewardship.

How the Company Makes Money

Kirin Holdings generates revenue through multiple streams, primarily from its sales of alcoholic beverages, including beer, wine, and spirits, which represent a significant portion of its income. The company operates various well-known brands, such as Kirin Lager and Ichiban Shibori, which are popular in both domestic and international markets. Additionally, Kirin earns income from its non-alcoholic beverage segment, which includes soft drinks, teas, and health drinks. The food products division, which encompasses dairy and processed foods, also contributes to the company's revenue. Strategic partnerships, such as collaborations with local and international breweries and beverage companies, enhance distribution and market reach, further driving sales. Factors such as consumer trends towards health and wellness, premiumization in beverages, and expansion into emerging markets also play vital roles in Kirin's revenue generation.

Kirin Holdings Co Financial Statement Overview

Summary

Kirin Holdings Co presents a mixed financial picture. The income statement shows stable margins but declining revenue growth, while the balance sheet indicates a balanced leverage position with low ROE. The cash flow statement highlights challenges in cash generation. The company needs to address its revenue growth and cash flow issues to improve its financial health and investor appeal.

Income Statement

Kirin Holdings Co shows a mixed performance in its income statement. The TTM (Trailing-Twelve-Months) data indicates a decline in revenue growth rate by 15.1%, which is concerning. However, the company maintains a stable gross profit margin of approximately 46% and a net profit margin of 2.26%. The EBIT and EBITDA margins are moderate at 5.11% and 11.82%, respectively. The decline in revenue growth is a significant weakness, but the stable margins provide some level of profitability.

Balance Sheet

The balance sheet of Kirin Holdings Co reflects a moderate financial position. The debt-to-equity ratio stands at 0.91, indicating a balanced leverage level. The return on equity (ROE) is relatively low at 4.70%, suggesting limited profitability from shareholders' equity. The equity ratio is approximately 34%, indicating a stable capital structure. While the company has managed its debt well, the low ROE is a concern for potential investors.

Cash Flow

Kirin Holdings Co's cash flow statement reveals some challenges. The free cash flow growth rate is negative at -3.59%, indicating a decline in available cash for reinvestment or distribution. The operating cash flow to net income ratio is 0.25, and the free cash flow to net income ratio is 0.08, both of which are relatively low. These metrics suggest that the company may face difficulties in generating sufficient cash flow relative to its net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.38T	2.34T	2.13T	1.99T	1.82T	1.85T
Gross Profit	1.10T	1.07T	963.47B	905.71B	822.84B	803.88B
EBITDA	276.58B	253.42B	294.80B	251.27B	227.59B	215.18B
Net Income	53.83B	58.21B	112.70B	111.01B	59.79B	71.94B
Balance Sheet
Total Assets	3.30T	3.35T	2.87T	2.54T	2.47T	2.46T
Cash, Cash Equivalents and Short-Term Investments	143.33B	127.19B	140.34B	96.44B	157.40B	169.62B
Total Debt	1.02T	857.57B	656.40B	523.12B	551.47B	642.64B
Total Liabilities	1.89T	1.82T	1.44T	1.29T	1.32T	1.36T
Stockholders Equity	1.12T	1.18T	1.13T	980.02B	894.18B	838.58B
Cash Flow
Free Cash Flow	17.03B	62.26B	89.40B	37.08B	132.97B	71.81B
Operating Cash Flow	201.39B	242.84B	203.21B	135.56B	219.30B	164.84B
Investing Cash Flow	-274.91B	-329.38B	-226.09B	-10.40B	-56.41B	-115.98B
Financing Cash Flow	115.52B	58.13B	35.91B	-167.84B	-180.46B	-52.47B

Kirin Holdings Co Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KNBWY, the sentiment is Positive. The current price of 14.54 is above the 20-day moving average (MA) of 14.41, above the 50-day MA of 14.54, and above the 200-day MA of 14.16, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 66.88 is Neutral, neither overbought nor oversold. The STOCH value of 87.19 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KNBWY.

Kirin Holdings Co Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BUD	75 Outperform	$125.21B	17.59	8.97%	1.67%	-2.06%	21.03%
ABEV	75 Outperform	$39.39B	13.56	15.97%	1.79%	-0.68%	4.29%
FMX	73 Outperform	$19.70B	42.83	5.48%	4.61%	1.44%	-38.87%
CCU	70 Neutral	$2.32B	16.34	9.07%	3.71%	16.59%	1.72%
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
KNBWY	58 Neutral	$12.26B	21.92	6.93%	2.27%	4.97%	-60.57%
TAP	56 Neutral	$9.26B	―	-17.66%	4.02%	-4.01%	-339.22%

Kirin Holdings Co Corporate Events

Kirin Holdings’ Citicoline Study: A Potential Game-Changer for Mood Enhancement?

Study Overview: Kirin Holdings Company, Limited is conducting a clinical trial titled ‘Exploring the Effects of Citicoline Supplementation on Validated Subjective and Objective Markers of Mood in Healthy Volunteers: A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial.’ The study aims to evaluate the impact of citicoline on mood in healthy adults, highlighting its potential significance in mental health research.

Kirin Holdings’ LC-Plasma Study: A Potential Game-Changer in Preventing URTIs

Study Overview: Kirin Holdings Company, Limited, in collaboration with RDC Clinical Pty Ltd, is conducting a study titled A Randomized Controlled Trial Evaluating the Efficacy of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria in Preventing Upper Respiratory Tract Infections and Reducing Symptom Severity and Duration. The study aims to assess the effectiveness of LC-Plasma in preventing upper respiratory tract infections (URTIs) among healthy volunteers, highlighting its potential significance in public health.

Kirin Holdings’ LC-Plasma Study: A Potential Game-Changer in Immune Health

Study Overview: Kirin Holdings Company, Limited is collaborating with RDC Clinical Pty Ltd on a study titled ‘The Effects of Lactococcus Lactis JCM 5805 (LC-Plasma) Lactic Acid Bacteria on Immune Response and Reducing Symptoms of Upper Respiratory Infectious Disease in Australian Healthy Adults.’ This randomized, placebo-controlled, double-blind study aims to assess how LC-Plasma affects the immune system and its efficacy in reducing symptoms of upper respiratory infections in healthy adults.